Long-Term Impact of COVID-19 on Disorders of Gut-Brain Interaction: Incidence, Symptom Burden, and Psychological Comorbidities.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Marasco Giovanni, Hod Keren, Colecchia Luigi, Cremon Cesare, Barbaro Maria Raffaella, Cacciari Giulia, Falangone Francesca, Kagramanova Anna, Bordin Dmitry, Drug Vasile, Miftode Egidia, Fusaroli Pietro, Mohamed Salem Youssef, Ricci Chiara, Bellini Massimo, Rahman M Masudur, Melcarne Luigi, Santos Javier, Lobo Beatriz, Bor Serhat, Yapali Suna, Akyol Deniz, Sapmaz Ferdane Pirincci, Urun Yonca Yilmaz, Eskazan Tugce, Celebi Altay, Kacmaz Huseyin, Ebik Berat, Binicier Hatice Cilem, Bugdayci Mehmet Sait, Yağcı Munkhtsetseg Banzragch, Pullukcu Husnu, Kaya Berrin Yalınbas, Tureyen Ali, Hatemi İbrahim, Koc Elif Sitre, Sirin Goktug, Calıskan Ali Riza, Bengi Goksel, Alıs Esra Ergun, Lukic Snezana, Trajkovska Meri, Dumitrascu Dan, Pietrangelo Antonello, Corradini Elena, Simren Magnus, Sjolund Jessica, Tornkvist Navkiran, Ghoshal Uday C, Kolokolnikova Olga, Colecchia Antonio, Serra Jordi, Maconi Giovanni, De Giorgio Roberto, Danese Silvio, Portincasa Piero, Di Sabatino Antonio, Maggio Marcello, Philippou Elena, Lee Yeong Yeh, Salvi Daniele, Venturi Alessandro, Borghi Claudio, Zoli Marco, Gionchetti Paolo, Viale Pierluigi, Stanghellini Vincenzo, Barbara Giovanni, GI‐COVID19 study groups
Аннотация
OBJECTIVES: To examine the long-term gastrointestinal symptom progression and psychological comorbidities in patients with post-COVID-19 DGBI, patients with pre-existing IBS/FD and non-DGBI controls.
METHODS: This post hoc analysis of a prospective multicenter cohort study reviewed patient charts for demographic data and medical history. Participants completed the Gastrointestinal Symptom Rating Scale at four time points: baseline, 1, 6, and 12 months, and the Hospital Anxiety and Depression Scale at 6 and 12 months. The cohort was divided into three groups: (1) post-COVID-19 DGBIs (2) non-DGBI, and (3) pre-existing IBS/FD, with the post-COVID-19 DGBIs group compared to the latter two control groups.
RESULTS: Among 599 eligible patients, 27 (4.5%) were identified as post-COVID-19 DGBI. This group experienced worsening abdominal pain, hunger pain, heartburn, and acid regurgitation, unlike symptom improvement or stability in non-DGBI controls (p < 0.001 for all symptoms, except hunger pain, p = 0.001). While patients with pre-existing IBS/FD improved in most gastrointestinal symptoms but worsened in constipation and incomplete evacuation, patients with post-COVID-19 DGBI exhibited consistent symptom deterioration across multiple gastrointestinal domains. Anxiety and depression remained unchanged in patients with post-COVID-19 DGBI, contrasting with significant reductions in controls (non-DGBI: p = 0.003 and p = 0.057; pre-existing IBS/FD: p = 0.019 and p = 0.007, respectively).
CONCLUSIONS: COVID-19 infection is associated with the development of newly diagnosed DGBIs and distinct symptom trajectories when compared with patients with pre-existing IBS/FD. Patients with post-COVID-19 DGBI experience progressive gastrointestinal symptom deterioration and persistent psychological distress, underscoring the need for tailored management strategies for this unique subgroup.